Watchdog to free up flow of cancer drugs
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The government has decided to prescribe two drugs to women with cancer regardless of the cost in a move against the "postcode lottery" that operates inside the National Health Service, the BBC reported on Tuesday.
The BBC said it had learnt that the health service watchdog, the National Institute for Clinical Excellence, had told health authorities not to restrict the drugs on grounds of cost.
The two drugs are Taxol and Taxotere, which can slow the spread of cancer and extend patients' lives.
Until now, it has been a matter of chance whether patients were prescribed the drugs as some health authorities said they were too expensive.
Taxol, made by Bristol-Myers Squibb Co, is mainly used to treat ovarian cancer while Taxotere, from Aventis Pharmaceuticals is used to fight breast cancer.
Campaigners welcomed the news, saying it would help Britain catch up with the rest of the world in treating cancer.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments